At the European Organ-On-Chip Society meeting we will present: “3D Human Tissues Within The MIVO-Multi In Vitro Organ Fluidic Device for Improving The Outcome Of In Vitro Drug Testing Assays” to demonstrate how the MIVO® platform combined with 3D human tissues can they represent a novel, highly reliable and easy to use in vitro model of interface phenomena for the study of the passage of bioactive drug molecules and their effect on cell behavior.
Another important appointment for React4life in an European contest. We are speaking about the annual meeting Euroocs, the European Organ-on-chip- society, organized and supported by the University of Twente in Netherlands.
The conferences, that this year will be on virtual mood, are scheduled on 8 and 9 July 2020, where the most recent results related to research, development and application of OoC will be presented and discussed.
The Euroocs is a very essential event for React4life: the meeting in fact addresses all areas of the of organs on-chip multidisciplinary field like Microfluidics, Cellular engineering, Developmental biology, Drug delivery, 3D cell cultures, Organoids and organ-specific models.
We are very proud to participate as speaker. Our CSO, Ing. Silvia Scaglione, infact, in the afternoon of Wednesday 8th July, presents our organ-on-chip technology, MIVO device (https://www.react4life.com/mivo-technology/) with her poster titled: “3D Human Tissues Within The MIVO-Multi In Vitro Organ Fluidic Device for Improving The Outcome Of In Vitro Drug Testing Assays”; she will explain how our fluid-dynamic multi-chamber device resembling the in vivo systemic circulation and the organ-organ fluidic connections.
The MIVO® -Multi In Vitro Organ device has been already validated in various applications such as the intestinal permeability of the molecules and the absorption of the medical device through the skin tissues; in this event it will be presented for its characteristic of resembling the systemic transport mechanisms in vivo of the drug and to test the effectiveness of the drug (i.e. cisplatin) against a tumor loaded with 3D cells. 3D human tumor tissues were grown inside the MIVO chamber and analyzed in terms of tumor regression over time; cell viability was measured metabolically, while the spread of the drug within the 3D tumor mass was measured by HPLC analysis.
Our poster will show how biochemical and biological results confirm that the MIVO® platform combined with 3D human tissues can they represent a novel, highly reliable and easy to use in vitro model of interface phenomena for the study of the passage of bioactive drug molecules and their effect on cell behavior.